Back to search

Article

Exploring the Lived Experiences of Individuals with Cystic Fibrosis After the Implementation of Trikafta® for Treatment.

2025-12-03

Abstract excerpt

<title>Abstract</title> <p> <bold>Background:</bold> CFTR-modulators are a class of medications prescribed to people with cystic fibrosis (pwCF) who have certain genetic mutations. In 2019, Trikafta <sup>®</sup> was approved by the FDA and lead to significant health improvements for pwCF including increased pulmonary function, a decrease in sweat chloride levels, and an overall increase in health-related qual...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d2380ef9-9468-5459-befb-633ca6fefd13
DOI
10.21203/rs.3.rs-7989348/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Exploring the Lived Experiences of Individuals with Cystic Fibrosis After the Implementation of Trikafta® for Treatment.DOI 10.21203/rs.3.rs-7989348/v1
Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals.Semantic proximity
Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.Semantic proximity
Standards for the care of people with cystic fibrosis; establishing and maintaining health.Semantic proximity
Navigating Change – UK specialised adult cystic fibrosis service delivery in the highly effective modulator therapy eraSemantic proximity
Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study.Semantic proximity
Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.Semantic proximity
Experiences of individuals receiving an adult diagnosis of Cystic Fibrosis : an interpretative phenomenological analysisSemantic proximity
A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.Semantic proximity
Changes in Care during the COVID-19 Pandemic for People with Cystic Fibrosis.Semantic proximity
Parenthood impacts short-term health outcomes in people with cystic fibrosis.Semantic proximity
Rethinking CF organization of care in the era of highly effective modulator: a nationwide research program HORIZONSemantic proximity
Exploring the views of people living with pulmonary fibrosis and health professionals on genetic testing in PF: A qualitative studySemantic proximity
Select a neighboring publication to make it the new centre.